Product Center
Ab&B Bio-Tech Co., Ltd. JS's Tetravalent Influenza Virus Subunit Vaccine Approved for Launch
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-05-18
- Views:
(Summary description)Recently, Ab&B Bio-Tech Co., Ltd. JS's independently developed full-dose adjuvant-free tetravalent influenza virus subunit vaccine (Huier Kangxin®) has been approved for marketing by the National Medical Products Administration (NMPA), marking China's first approved tetravalent influenza virus subunit vaccine.
Ab&B Bio-Tech Co., Ltd. JS's Tetravalent Influenza Virus Subunit Vaccine Approved for Launch
(Summary description)Recently, Ab&B Bio-Tech Co., Ltd. JS's independently developed full-dose adjuvant-free tetravalent influenza virus subunit vaccine (Huier Kangxin®) has been approved for marketing by the National Medical Products Administration (NMPA), marking China's first approved tetravalent influenza virus subunit vaccine.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-05-18 11:00
- Views:
Huier Kangxin® extracts only effective antigens, featuring high purity, low vaccination side effects, excellent safety profile, and comprehensive protection, and is classified as a Category 1 preventive biological product. The clinical trial results all reached the primary endpoints and were published in the international authoritative journal Vaccine, and were cited by the Technical Guidelines for Influenza Vaccination in China (2021-2022) and Technical Guidelines for Influenza Vaccination in China (2022-2023) respectively.
Clinical results show that Huier Kangxin® is a safe and effective influenza vaccine that can provide broader and more robust protection against seasonal influenza viruses. The vaccine is expected to serve as an important component of influenza prevention strategies and contribute to global influenza prevention and control efforts.
Ab&B Bio-Tech Co., Ltd. JS is committed to the research and development, regulatory submission, industrial production, and commercialization of innovative human vaccines. The company adheres to international standards and conducts independent innovation research. Currently, the quadrivalent influenza virus subunit vaccine (for 6-35 months old), quadrivalent influenza virus subunit vaccine (for 3 years old and above), 23-valent pneumococcal polysaccharide vaccine, and freeze-dried human rabies vaccine (human diploid cell) have all obtained clinical trial approvals, with clinical trials and New Drug Applications (NDA) progressing in an orderly manner.
In recent years, the company has continued to increase R&D investment. The Shanghai/Taizhou R&D Center and pilot test platform are advancing multiple pipelines including viral vaccines, bacterial vaccines, conjugate vaccines, recombinant subunit vaccines, and mRNA vaccines simultaneously.
Avoiding imitation, focusing on international trends, and developing innovative vaccines are the guiding principles of Ab&B Bio-Tech Co., Ltd. JS. "Caring for life and protecting health" is the mission of Ab&B Bio-Tech Co., Ltd. JS! The company will uphold the spirit of innovation, pragmatism, self-discipline, integrity, and persistent dedication, striving to make global innovative vaccines accessible in China and deliver high-quality Chinese vaccines to the world!
Relevant information
-
The Launch Meeting of Phase I/II Clinical Trial for Recombinant Herpes Zoster Vaccine (CHO Cell) was successfully heldRecently, the Phase I/II clinical trial launch meeting for the recombinant herpes zoster vaccine (CHO cell), co-developed by Ab&B Bio-Tech CO., LTD. JS. and Yither Biotech (Shanghai) Co., Ltd., was successfully held in Henan, and the first-in-human (FIH) dosing was successfully completed. - Ab&B Bio and Yither Bio Have Both Obtained Qualification Certification! 12-30
- Kickoff Meeting for Clinical Research on Quadrivalent Influenza Virus Subunit Vaccine in Children with Nephrotic Syndrome Successfully Held 12-25
- IND Application for Influenza Virus Subunit Vaccine (Adjuvanted) Approved 10-30
- The Application for the Marketing of Trivalent Influenza Virus Subunit Vaccine has been Accepted! 10-08
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
